• LAST PRICE
    2.3000
  • TODAY'S CHANGE (%)
    Trending Down-0.0500 (-2.1277%)
  • Bid / Lots
    2.3000/ 5
  • Ask / Lots
    2.4500/ 1
  • Open / Previous Close
    2.3900 / 2.3500
  • Day Range
    Low 2.2700
    High 2.4500
  • 52 Week Range
    Low 2.2700
    High 46.0000
  • Volume
    20,368
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 2.35
TimeVolumeGNPX
09:32 ET4392.39
09:34 ET1502.34
09:45 ET8002.426
09:56 ET3002.3536
09:59 ET17002.28
10:01 ET2332.34
10:08 ET1002.34
10:19 ET6002.36
10:26 ET1052.2701
10:48 ET1002.3101
12:05 ET3342.34
12:12 ET11002.36
12:36 ET1002.4
01:37 ET1002.4138
01:57 ET9852.45
02:58 ET2002.4
03:02 ET2002.375
03:14 ET1002.4
03:20 ET39162.33
03:30 ET43302.28
03:54 ET1232.3001
03:56 ET2252.34
03:59 ET10292.3
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGNPX
Genprex Inc
4.5M
-0.1x
---
United StatesNEXI
Neximmune Inc
4.6M
-0.1x
---
United StatesARTL
Artelo Biosciences Inc
4.6M
-0.5x
---
United StatesKTRA
Kintara Therapeutics Inc
4.3M
0.0x
---
United StatesTHAR
Tharimmune Inc
4.3M
0.0x
---
United StatesSNPX
Synaptogenix Inc
4.8M
-0.1x
---
As of 2024-04-16

Company Information

Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on the development of gene-based therapies for patients with unmet medical needs. The Company's lead oncology drug candidate, REQORSA Immunogen therapy drug (quaratusugene ozeplasmid), is being developed to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. REQORSA consists of the TUSC2 gene-expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules (its ONCOPREX Nanoparticle Delivery System). The Company is also using a different gene therapy delivery system in developing its pre-clinical diabetes candidates, GPX-002 and GPX-003. Its diabetes gene therapy is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.

Contact Information

Headquarters
1601 Trinity Street Bldg. B, Suite 3.322AUSTIN, TX, United States 78712
Phone
512-537-7997
Fax
302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer, Co-Founder
J. Rodney Varner
Chief Financial Officer
Ryan Confer
Executive Vice President, General Counsel, Chief Strategy Officer
Catherine Vaczy
Senior Vice President - Regulatory Affairs
Suzanne Thornton-Jones
Chief Manufacturing and Technology Officer
Hemant Kumar

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$4.5M
Revenue (TTM)
$0.00
Shares Outstanding
1.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.56
EPS
$-22.93
Book Value
$4.99
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.